Home Tags Amgen

Tag: Amgen

Amgen and Synafix Sign US $2 Billion License Agreement

Netherlands-based Synaffix, a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), confirmed that it had signed...

Amgen and CytomX Therapeutics Agree to Jointly Develop T-Cell Engaging Bispecific...

Amgen and CytomX Therapeutics have entered into a strategic collaboration to co-develop a Probody™ T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR),...

Advancements in Bispecific Antibody Immunotherapy Development

The 15th annual Cambridge Healthcare Institute’s PepTalk - Protein Science Week, one of the largest gatherings of protein science researchers in the world, was recently...

Blinatumomab Shows Positive Outcomes in Acute Lymphoblastic Leukemia

Data presented during the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, Florida shows that Amgen’s blinatumomab (Blincyto®)...

X